Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atengenal and Astugenal in DIPG
NCT02742883Phase 2Suspended
- Sponsor
- Burzynski Research Institute
- Start
- Apr 2016
- Primary completion
- Mar 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in diffuse intrinsic pontine glioma (DIPG), sponsored by Burzynski Research Institute. Started Apr 2016; status: suspended.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02742883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742883.